trending Market Intelligence /marketintelligence/en/news-insights/trending/hxR1Qy7oblp6HJKSjt03vA2 content esgSubNav
In This List

Orexigen prevails in patent litigation against Teva unit

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Orexigen prevails in patent litigation against Teva unit

Orexigen Therapeutics Inc.'s weight-loss therapy Contrave will continue to have market exclusivity after a U.S. court favored the company in its patent litigation lawsuit against Actavis Laboratories FL Inc.

The U.S. District Court for the District of Delaware upheld the validity of all the patents involved in the case, with exclusivity through 2030.

Actavis Laboratories, a unit of Teva Pharmaceutical Industries Ltd., was looking to market a generic version of the drug.